Puma Biotechnology, Inc.

PBYI Healthcare Biotechnology

Puma Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $228.4 million, down 0.91% from fiscal 2024. In the quarter to June 2026, revenue grew 7.75%, EPS grew 33.3%, free cash flow fell 88.5% and total debt fell 79.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

9.83 0.69 −6.56%
Market cap
$543.0M
P/E
18.2×
Fwd P/E
24.2×
Dividend yield
—
F-score
8/9
Altman Z
−4.16
Beneish M
−2.06
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Total current assets
162.69 147.66 156.19 134.28 140.02 146.14 166.30 203.00 106.39 236.47
Total non-current assets
53.62 65.68 74.34 87.78 86.56 98.08 68.61 56.12 59.13 16.32
Total Assets
216.30 213.33 230.53 222.06 226.59 244.22 234.91 259.12 165.53 252.79
Total current liabilities
81.25 96.11 99.38 77.48 109.59 114.26 90.84 67.12 58.34 37.46
Total non-current liabilities
4.71 25.10 77.70 122.97 119.45 135.92 126.61 157.70 53.88 5.51
Total liabilities
85.96 121.21 177.09 200.45 229.03 250.17 217.44 224.82 112.22 42.97
Common Equity (Total)
130.34 92.13 53.44 21.61 (2.45) (5.95) 17.46 34.31 53.30 209.82
Shareholders Equity (Total)
130.34 92.13 53.44 21.61 (2.45) (5.95) 17.46 34.31 53.30 209.82
Total Debt
22.52 67.05 99.66 102.45 100.67 98.31 97.59 151.89 48.48 —

Show all line items

In millions of $ except per-share values · columns are period end dates